Rocket Pharmaceuticals, Inc. (RCKT) financial statements (2021 and earlier)

Company profile

Business Address 350 FIFTH AVENUE
NEW YORK, NY 10118
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:483304213100126111
Cash and cash equivalents297185111793080
Short-term investments18611994219731
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)7   
Deferred costs     2
Other undisclosed current assets54(4)12(1)
Total current assets:487308209101128112
Noncurrent Assets
Finance lease, right-of-use asset51 
Operating lease, right-of-use asset12
Property, plant and equipment19292111
Long-term investments and receivables  7   
Long-term investments  7   
Intangible assets, net (including goodwill)313131   
Goodwill313131   
Deposits noncurrent assets001   
Restricted cash and investments221   
Other noncurrent assets   000
Other undisclosed noncurrent assets 0    
Total noncurrent assets:1036442111
TOTAL ASSETS:591372251102130113
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:251715474
Accounts payable14 022
Accrued liabilities211243
Employee-related liabilities532   
Interest and dividends payable11111 
Other undisclosed accounts payable and accrued liabilities16811   
Debt71    
Other undisclosed current liabilities1     
Total current liabilities:331815474
Noncurrent Liabilities
Long-term debt and lease obligation554641   
Long-term debt, excluding current maturities354541   
Finance lease, liability19 
Operating lease, liability01
Liabilities, other than long-term debt000000
Deferred rent credit  0
Other liabilities00 000
Other undisclosed noncurrent liabilities   5049 
Total noncurrent liabilities:55474250490
Total liabilities:87655754565
Stockholders' equity
Stockholders' equity attributable to parent5043071944873109
Common stock110000
Treasury stock, value (0)(1)   
Additional paid in capital826490300316312305
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)(0)
Accumulated deficit(323)(183)(106)(268)(239)(196)
Total stockholders' equity:5043071944873109
TOTAL LIABILITIES AND EQUITY:591372251102130113

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(134)(76)(71)(27)(42)(20)
Operating loss:(134)(76)(71)(27)(42)(20)
Nonoperating income
(Investment Income, Nonoperating)
   100
Interest and debt expense(7)(6)(6)(4)(1)(1)
Net loss:(141)(82)(77)(29)(43)(22)
Other undisclosed net income (loss) attributable to parent253  (46)
Net loss attributable to parent:(140)(77)(75)(29)(43)(68)
Preferred stock dividends and other adjustments     (0)
Net loss available to common stockholders, diluted:(140)(77)(75)(29)(43)(68)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(141)(82)(77)(29)(43)(22)
Other undisclosed comprehensive income (loss)   0(0)(46)
Comprehensive loss:(141)(82)(77)(29)(43)(68)
Other undisclosed comprehensive income, net of tax, attributable to parent253   
Comprehensive loss, net of tax, attributable to parent:(140)(77)(75)(29)(43)(68)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: